Dr Sarita Shrivastva

Dr. Sarita Shrivastva holds a an MBBS, an MD in Radiation Oncology and DM in Medical Oncology along with MRCP (UK) and SCE in Medical Oncology reflecting strong credentials and advanced oncology training. Her support expert care across both solid tumors and blood related cancers.

She has experience in managing a wide range of cancers including brain tumors, head and neck cancers, breast cancer, lung cancer, thyroid cancer and gastrointestinal cancers such as esophageal, stomach, liver pancreatic and colorectal cancers. Her practice also includes gynecological cancers like ovarian, uterine and cervical cancers.

Dr. Shrivastva is well-versed in treating urological cancers including kidney, bladder, prostate, and testicular cancers, as well as sarcoma, melanoma and other skin cancers. She also provides specialized care for lymphoma, leukemia and multiple myeloma, ensuring a multidisciplinary approach to cancer treatment.

Her clinical interests include advanced therapies such as targeted therapy, immunotherapy and hormonal therapy which aim to treat cancer more precisely with fewer side effects. She is experienced in bone marrow transplantation cancer screening and genetic counselling for hereditary cancers.

In addition to these treatments, Dr. Shrivastva emphasizes pain management and supportive care is helping patients maintain comfort and quality of life throughout their treatment journey. She also offers second opinion consultations to help patients make informed decisions.

Dr. Sarita Shrivastva is available for consultations at Medicover Hospitals, Hyderabad, Monday to Saturday from 10:00 AM to 4:00 PM.

Past Experience

• Worked as Consultant Medical and hemato oncologist at Cion cancer clinics

Awards & Achievements

• Winner of 42nd National Level ICON Quiz, Mar' 20, Hyderabad
• Winner of 41st National Level ICON Quiz, Sep'19, Ahmedabad
• Winner of 40th National Level ICON Quiz, Mar'19, Kolkata
• Winner in Poster Presentation in National
• Conference of ISMPOCON, 2018, Jaipur
• Presentations At National & International Conferences:
• Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single center experience - ESMO ASIA, SINGAPORE, NOVEMBER 2019
• Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario - ESMO BREAST CANCER ANNUAL CONGRESS, BERLIN, GERMANY 2019
• Clinico-pathological profile, treatment and outcomes of metastatic gastric cancer: an institutional experience - 40TH ICON CONFERENCE, KOLKATA 2019
• Anaplastic lymphoma kinase positive advanced nsclc: An institutional experience -ISMPOCON JAIPUR 2018

Memberships

• Member of European Society of Medical Oncology (ESMO)
• Member of Association of Radiation Oncologists of India (AROI)